<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9371">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00756730</url>
  </required_header>
  <id_info>
    <org_study_id>08-09</org_study_id>
    <nct_id>NCT00756730</nct_id>
  </id_info>
  <brief_title>Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r</brief_title>
  <acronym>LARD</acronym>
  <official_title>Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Skiest, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Community Research Initiative of New England</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      For participants with HIV taking either lopinavir or fosamprenavir who have elevated
      triglycerides, this trial will study the change in triglycerides after switching protease
      inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase IV trial will look at lipid and virologic responses after a switch to a more
      lipid-friendly antiretroviral regimen. Participants will be randomized to receive either
      boosted atazanavir or boosted darunavir given once daily, along with background NRTIs. This
      24-week study will require 4 visits after randomization for evaluation, monitoring, and lab
      studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24.</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>A 10% decline in triglycerides (TGs) was determined to be clinically significant. The percentage of people that experienced a 10% decline was calculated by dividing the number who had a decline of 10% TGs by the total number of participants in the arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change in Fasting Triglyceride Level From Baseline to Week 24</measure>
    <time_frame>Baseline to week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Patients With HIV VL &lt;200 Copies/mL at Week 4, 12 &amp; 24</measure>
    <time_frame>Week 4, 12 &amp; 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in CD4 From Baseline to Week 24</measure>
    <time_frame>baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol in the Two Study Groups at 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol at Week 24</measure>
    <time_frame>week 24</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol at Week 24</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Switch to DRV/r (800mg/100mg) QD</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch to ATV/r (300mg/100mg QD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATV/r</intervention_name>
    <description>Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.</description>
    <arm_group_label>Switch to ATV/r (300mg/100mg QD)</arm_group_label>
    <other_name>Atazanavir/r</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DRV/r</intervention_name>
    <description>We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.</description>
    <arm_group_label>Switch to DRV/r (800mg/100mg) QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently receiving Antiretroviral Therapy (ART) regimen including LPV/r or FPV/r and
             &gt; or equal to 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Patient must be
             on a stable regimen containing LPV/r or FPV/r for at least 12 weeks prior to
             screening.

          -  Documentation of an undetectable Human Immunodeficiency Virus (HIV) viral load
             (VL&lt;400 copies/ml) using an FDA approved assay for a minimum of twelve weeks prior to
             screening AND undetectable HIV viral load using an FDA approved ultrasensitive assay
             at screening.

          -  No evidence of HIV protease resistance as defined by the Stanford HIV database

          -  Currently receiving first protease inhibitor unless switch to LPV/r or FPV/r was for
             non-virologic reasons

          -  Fasting triglycerides &gt; 200 mg/dL

          -  No ongoing issues that in the opinion of the investigator would lead to decreased
             ability to comply with the study procedures

          -  If currently receiving a proton pump inhibitor, the dose is &lt; omeprazole 20 mg or the
             equivalent dose of another proton pump inhibitor

          -  If patient is receiving another lipid lowering medication, it must be at a stable
             dose

        Exclusion Criteria:

          -  Currently receiving an ART regimen other than &gt; or equal to two NRTIs and either
             LPV/r or FPV/r

          -  Prior use of darunavir or atazanavir

          -  CDC Class C Illness diagnosed within 30 days of screening

          -  Patient is currently receiving the following Hydroxamethylglutaryl-coA (HMGCoA)
             reductase inhibitor medications (statins): pravastatin, lovastatin, simvastatin

          -  Patient is currently receiving a bile acid sequestrant (cholestyramine, colestipol,
             and colesevelam)

          -  Grade 3 or 4 Laboratory abnormalities as defined by a standardized grading scheme
             based on the DAIDS table with the following exceptions:

               1. Pre-existing diabetes mellitus with asymptomatic, nonfasting glucose grade 3
                  elevations

               2. Subjects with asymptomatic grade 3 fasting triglyceride or cholesterol
                  elevations

          -  Clinical or laboratory evidence of clinically significant liver
             impairment/dysfunction disease or cirrhosis

          -  Note: Individuals co-infected with chronic hepatitis B or C viruses will be allowed
             to enter the trial if their condition is clinically stable and they will not require
             therapy during the course of the study. Individuals diagnosed with acute viral
             hepatitis at screening will not be allowed to enroll during acute phase

          -  Active substance abuse or significant psychiatric illness that in the opinion of the
             investigator might interfere with study compliance

          -  Use of any investigational agents 30 days prior to screening

          -  Life expectancy &lt; 6 months in the opinion of the investigator

          -  Pregnancy or breast feeding

          -  Female subject of childbearing potential (i.e., heterosexually active, and not
             surgically sterile or at least two years post-menopausal) not using effective
             non-hormonal birth control methods or not willing to continue practicing these birth
             control methods from screening until the last trial related activity
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Skiest, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Research Initiative</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spectrum Medical Group</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>02319</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative - West</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Infectious Disease and Travel Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Community Health Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Fight</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>David M. Lee, M.D., P.A., a/b/a Uptown Physicians Group</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nicholaos C. Bellos, MD, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 23, 2012</lastchanged_date>
  <firstreceived_date>September 18, 2008</firstreceived_date>
  <firstreceived_results_date>February 21, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Community Research Initiative of New England</investigator_affiliation>
    <investigator_full_name>Daniel Skiest, MD</investigator_full_name>
    <investigator_title>Associate Research Director</investigator_title>
  </responsible_party>
  <keyword>lopinavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>atazanavir</keyword>
  <keyword>fosamprenavir</keyword>
  <keyword>darunavir</keyword>
  <keyword>anti-retroviral</keyword>
  <keyword>AIDS</keyword>
  <keyword>HIV</keyword>
  <keyword>LARD</keyword>
  <keyword>triglyceride</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>treatment Experienced</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atazanavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Fosamprenavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
        </group>
        <group group_id="P2">
          <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>discontinued due to rash prior to week 4</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>persistent low-level viremmia</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
        </group>
        <group group_id="B2">
          <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="48" lower_limit="34" upper_limit="67"/>
                <measurement group_id="B2" value="46" lower_limit="30" upper_limit="60"/>
                <measurement group_id="B3" value="47" lower_limit="30" upper_limit="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="12"/>
                <measurement group_id="B3" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="29"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="25"/>
                <measurement group_id="B2" value="24"/>
                <measurement group_id="B3" value="49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>CD4 Count</title>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="584" lower_limit="249" upper_limit="996"/>
                <measurement group_id="B2" value="554" lower_limit="31" upper_limit="1066"/>
                <measurement group_id="B3" value="569" lower_limit="31" upper_limit="1066"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Viral Load</title>
          <units>copies/mL</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="NA">VL was not detected. All values were reported less than 50 copies/ml, the lower limit of detection.</measurement>
                <measurement group_id="B2" value="NA">VL was not detected. All values were reported less than 50 copies/ml, the lower limit of detection.</measurement>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline antiretroviral medications - Protease inhibitors</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Lopinavir/ritonavir (LPV/r)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="23"/>
                <measurement group_id="B3" value="46"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>fosamprenavir/ritonavir (FPV/r)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Baseline medications - Nucleoside analogs</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>viread (TDF)/emtriva (FTC)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="17"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>ziagen (ABC)/Epivir (3TC)</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Lipid Lowering Medications</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>statin</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>fibrate</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="11"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>fish oil</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>niacin</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>none</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24.</title>
        <description>A 10% decline in triglycerides (TGs) was determined to be clinically significant. The percentage of people that experienced a 10% decline was calculated by dividing the number who had a decline of 10% TGs by the total number of participants in the arm.</description>
        <time_frame>baseline, 24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia. Neither subject met criteria for virologic failure.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24.</title>
            <description>A 10% decline in triglycerides (TGs) was determined to be clinically significant. The percentage of people that experienced a 10% decline was calculated by dividing the number who had a decline of 10% TGs by the total number of participants in the arm.</description>
            <units>percentage of patients</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="73"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Patients With HIV VL &lt;200 Copies/mL at Week 4, 12 &amp; 24</title>
        <time_frame>Week 4, 12 &amp; 24</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Patients With HIV VL &lt;200 Copies/mL at Week 4, 12 &amp; 24</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Week 4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 12</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 24</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                  <measurement group_id="O2" value="100"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference in CD4 From Baseline to Week 24</title>
        <time_frame>baseline to Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Difference in CD4 From Baseline to Week 24</title>
            <units>cells/mm^3</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10.75" spread="17.67"/>
                  <measurement group_id="O2" value="14.28" spread="19.77"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol in the Two Study Groups at 24 Weeks</title>
        <time_frame>Week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Total Cholesterol in the Two Study Groups at 24 Weeks</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="195" lower_limit="110" upper_limit="311"/>
                  <measurement group_id="O2" value="195" lower_limit="132" upper_limit="304"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>LDL Cholesterol at Week 24</title>
        <time_frame>week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>LDL Cholesterol at Week 24</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="116" lower_limit="55" upper_limit="180"/>
                  <measurement group_id="O2" value="111" lower_limit="46" upper_limit="204"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HDL Cholesterol at Week 24</title>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>HDL Cholesterol at Week 24</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38" lower_limit="22" upper_limit="54"/>
                  <measurement group_id="O2" value="40" lower_limit="26" upper_limit="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL</title>
        <time_frame>24 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="48"/>
                  <measurement group_id="O2" value="55"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change in Fasting Triglyceride Level From Baseline to Week 24</title>
        <time_frame>Baseline to week 24</time_frame>
        <safety_issue>No</safety_issue>
        <population>Two patients in the ATV/r arm discontinued prior to week 24: 1 due to a grade 2 rash, and one due to low level viremia.</population>
        <group_list>
          <group group_id="O1">
            <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
          </group>
          <group group_id="O2">
            <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
            <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="25"/>
                  <measurement group_id="O2" value="22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Change in Fasting Triglyceride Level From Baseline to Week 24</title>
            <units>mg/dL</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-126" lower_limit="-312" upper_limit="133"/>
                  <measurement group_id="O2" value="-88" lower_limit="-469" upper_limit="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to 24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Switch to Darunavir/Ritonavir (DRV/r) , 800mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to DRV/r, 800mg/100mg QD</description>
        </group>
        <group group_id="E2">
          <title>Switch to Atazanavir/Ritonavir (ATV/r), 300mg/100mg QD</title>
          <description>Virologically suppressed patients on a regimen containing Lopinavir/ritonavir (LPV/r) or fosamprenavir/ritonavir (FPV/r) were switched to ATV/r</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>possible bowel obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>alcohol withdrawal/suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urosepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Infection (URI)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel Skiest</name_or_title>
      <organization>Community Research initiavte</organization>
      <phone>413 794 5376</phone>
      <email>Daniel.Skiest@baystatehealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
